advertisement
Abstract #12260 Published in IGR 7-2
Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: A 24-month study
Polo V; Larrosa JM; Ferreras A; Honrubia FMAnnals of ophthalmology (Skokie, Ill.) 2005; 37: 33-36
OBJECTIVE: To compare the long-term efficacy and short-term escape from effective treatment of 0.005% latanoprost administered once daily vs 0.5% timolol plus 2% dorzolamide twice daily for 24 months to patients with open-angle glaucoma. DESIGN: Prospective study. SETTING AND NUMBER OF PATIENTS: A total of 117 eyes of 61 subjects with open-angle glaucoma were included in this study. The eligible patients were randomized to receive either 0.005% latanoprost once daily or 0.5% timolol and 2% dorzolamide twice daily. MEASUREMENTS: The intraocular pressure (IOP) figures were recorded at baseline and at 0. 5, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months of treatment. RESULTS: Compared with baseline measurements, both latanoprost and timolol plus dorzolamide treatments caused a significant (p < 0.001) reduction of IOP at each visit throughout the duration of therapy. The IOP was reduced to 17.1 ± 2.4, 16.6 ± 2.2, and 15.9 ± 2.04 with latanoprost and 18.2 ± 2.1, 18.6 ± 2.4, and 18.4 ± 1.9 with timolol plus dorzolamide after 6, 12, and 24 months, respectively. After 24 months, 82% of the patients who initially responded to treatment were still controlled in the latanoprost group, with a maintained reduction of IOP and no signs of upward drift. However, only 56% of the patients of the timolol plus dorzolamide group were controlled at the end of the study with increase of IOP figures. CONCLUSIONS: Administered once daily, 0.005% latanoprost is more effective than timolol plus dorzolamide twice daily for the long-term treatment of patients with open-angle glaucoma, showing a maintained effect on IOP reduction.
Dr. V. Polo, Miguel Servet University Hospital, Department of Ophthalmology, P Pamplona, 8-10 4 Dcha Esc Izda, 50.004, Zaragoza, Spain
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
